Publications of Céline KEMPENEERS
Bookmark and Share    
Full Text
See detailTotal absence of the pericardium associated with hypogammaglobulinemia and bronchiectasis in a girl
KINUANI MULASI, Rachel ULiege; BRUYERE, Pierre-Julien ULiege; Schoysman, Laurent et al

in Paediatric Reports (2019), 11(8250),

Detailed reference viewed: 20 (5 ULiège)
Full Text
See detailCiliary Functional Analysis: Beating a path towards standardisation
KEMPENEERS, Céline ULiege; Seaton, Claire; Garcia Espinosa, Bernardo et al

Poster (2019, October 18)

Detailed reference viewed: 14 (1 ULiège)
Full Text
See detailChronic cough in Pediatrics: Algorithms
KEMPENEERS, Céline ULiege

Speech/Talk (2018)

Detailed reference viewed: 17 (3 ULiège)
Full Text
See detailToux chronique chez l’enfant
KEMPENEERS, Céline ULiege

Speech/Talk (2018)

Detailed reference viewed: 17 (1 ULiège)
Full Text
See detailEtude rétrospective des lymphomes de l'enfant. A propos de 27 cas traités dans une méme institution
KEMPENEERS, Céline ULiege; FORGET, Patricia ULiege; DRESSE, Marie-Françoise ULiege et al

in Revue Médicale de Liège (2005), 60(11), 855-862

Childhood lymphomas represent a heterogeneous group of disorders that are quite different from adult lymphomas. Over the past three decades, empirical chemotherapeutic management has transformed survival ... [more ▼]

Childhood lymphomas represent a heterogeneous group of disorders that are quite different from adult lymphomas. Over the past three decades, empirical chemotherapeutic management has transformed survival figures, and more recently greater understanding of the biology is offering hope for improved management of resistant disease. We present here the experience of a single institution in the management of 27 childhood lymphomas; epidemiological and clinical characteristics are described as well as survival rates. The median follow up of the patients is 4 years 7 months. The five-year overall survival for the entire group is more than 95 %; the 5-year disease free survival is 91,6 % for Hodgkin's lymphomas, 92,8% for non Hodgkin's lymphomas and 100% for Burkitt diseases. Two relapses have occurred and all of them appeared within the 18 months of the diagnosis. No toxic death has been reported. [less ▲]

Detailed reference viewed: 31 (7 ULiège)